Clinical Trials at Rutgers Cancer Institute of New Jersey
As of August 2026, 107 paid clinical trials are recruiting at Rutgers Cancer Institute of New Jersey, located at 195 LITTLE ALBANY ST, NEW BRUNSWICK, NJ 08901-1914, phone (732) 235-6240 in New Brunswick, New Jersey. Active studies at this site cover conditions such as Breast Cancer, Acute Myeloid Leukemia and Breast Neoplasms. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in New Brunswick
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
108 clinical trials at Rutgers Cancer Institute of New Jersey
·Clear filters·A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Common conditions studied in New Brunswick
- Breast Cancer (14 active studies)
- Acute Myeloid Leukemia (11 active studies)
- Cancer (8 active studies)
- Breast Neoplasms (7 active studies)
- Melanoma (6 active studies)
- Multiple Myeloma (6 active studies)
Leading research sponsors in New Brunswick
- Rutgers, The State University of New Jersey
- National Cancer Institute (NCI)
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in New Brunswick?
There are approximately 341 recruiting clinical trials in New Brunswick, New Jersey listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Brunswick pay participants?
Most recruiting trials in New Brunswick compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Brunswick?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Brunswick?
The most common conditions under active study in New Brunswick include Breast Cancer (14), Acute Myeloid Leukemia (11), Cancer (8), Breast Neoplasms (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Brunswick?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Brunswick on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Brunswick?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Brunswick?
Recruiting research sites in New Brunswick include Rutgers Cancer Institute of New Jersey, Rutgers Cancer Institute, Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Brunswick right now?
The largest active categories in New Brunswick are Cancer & tumors (178), Diabetes & metabolic (13), Cardiovascular (12). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Rutgers Cancer Institute of New Jersey?
Rutgers Cancer Institute of New Jersey is located at 195 LITTLE ALBANY ST, NEW BRUNSWICK, NJ 08901-1914. Use the Google Maps link in the intro above to get directions.
How do I contact Rutgers Cancer Institute of New Jersey?
You can reach Rutgers Cancer Institute of New Jersey by phone at (732) 235-6240. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.